Abstract
Since the initial description one hundred years ago by Dr. Alois Alzheimer, the disorder that bears his name has been characterized by the occurrence of two brain lesions: amyloid plaques and neurofibrillary tangles (NFTs). Yet the precise relationship between beta-amyloid (Aβ) and tau, the two proteins that accumulate within these lesions, has proven elusive. Today, a growing body of work supports the notion that Aβ may directly or indirectly interact with tau to accelerate NFT formation. Here we review recent evidence that Aβ can adversely affect distinct molecular and cellular pathways, thereby facilitating tau phosphorylation, aggregation, mis-localization, and accumulation. Studies are presented that support four putative mechanisms by which Aβ may facilitate the development of tau pathology. A great deal of work suggests that Aβ may drive tau pathology by activating specific kinases, providing a straightforward mechanism by which Aβ may enhance tau hyperphosphorylation and NFT formation. In the AD brain, Aβ also triggers a massive inflammatory response and pro-inflammatory cytokines can in turn indirectly modulate tau phosphorylation. Mounting evidence also suggests that Aβ may inhibit tau degradation via the proteasome. Lastly, Aβ and tau may indirectly interact at the level of axonal transport and evidence is presented for two possible scenarios by which axonal transport deficits may play a role. We propose that the four putative mechanisms described in this review likely mediate the interactions between Aβ and tau, thereby leading to the development of AD neurodegeneration.
Keywords: Phosphorylation, inflammation, proteasome, axonal transport, neurofibrillary tangles, PHF, oligomer, amyloid
Current Alzheimer Research
Title: Pathways by Which Aβ Facilitates Tau Pathology
Volume: 3 Issue: 5
Author(s): Mathew Blurton-Jones and Frank M. LaFerla
Affiliation:
Keywords: Phosphorylation, inflammation, proteasome, axonal transport, neurofibrillary tangles, PHF, oligomer, amyloid
Abstract: Since the initial description one hundred years ago by Dr. Alois Alzheimer, the disorder that bears his name has been characterized by the occurrence of two brain lesions: amyloid plaques and neurofibrillary tangles (NFTs). Yet the precise relationship between beta-amyloid (Aβ) and tau, the two proteins that accumulate within these lesions, has proven elusive. Today, a growing body of work supports the notion that Aβ may directly or indirectly interact with tau to accelerate NFT formation. Here we review recent evidence that Aβ can adversely affect distinct molecular and cellular pathways, thereby facilitating tau phosphorylation, aggregation, mis-localization, and accumulation. Studies are presented that support four putative mechanisms by which Aβ may facilitate the development of tau pathology. A great deal of work suggests that Aβ may drive tau pathology by activating specific kinases, providing a straightforward mechanism by which Aβ may enhance tau hyperphosphorylation and NFT formation. In the AD brain, Aβ also triggers a massive inflammatory response and pro-inflammatory cytokines can in turn indirectly modulate tau phosphorylation. Mounting evidence also suggests that Aβ may inhibit tau degradation via the proteasome. Lastly, Aβ and tau may indirectly interact at the level of axonal transport and evidence is presented for two possible scenarios by which axonal transport deficits may play a role. We propose that the four putative mechanisms described in this review likely mediate the interactions between Aβ and tau, thereby leading to the development of AD neurodegeneration.
Export Options
About this article
Cite this article as:
Blurton-Jones Mathew and LaFerla M. Frank, Pathways by Which Aβ Facilitates Tau Pathology, Current Alzheimer Research 2006; 3 (5) . https://dx.doi.org/10.2174/156720506779025242
DOI https://dx.doi.org/10.2174/156720506779025242 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Solid-State Structure of Abeta (Aβ) in Alzheimer's Disease
Protein & Peptide Letters Cognitive Impairment in the Septic Brain
Current Neurovascular Research Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Fragile X Syndrome and Alzheimers Disease: Another Story About APP and β -Amyloid
Current Alzheimer Research Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia
Current Alzheimer Research Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Shear Stress-sensitive Carriers for Localized Drug Delivery
Current Pharmaceutical Design Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Current Pharmaceutical Design A Medicinal Mushroom: Phellinus Linteus
Current Medicinal Chemistry Accuracy of Ultrasound Imaging Technique for Assessing Lipoatrophy in HIV-Infected Subjects
Current HIV Research Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model
Current Alzheimer Research Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A
Current Vascular Pharmacology